Uflex Ltd Q2 FY2026 Concall Summary

Key Takeaways

• Guidance cut, margin pressure from imports: Full-year revenue growth halved to ~5% and EBITDA guided down to ₹1,800–₹1,850 crores as BOPET imports surged ~120% YoY, forcing domestic price cuts.
• BOPP shortage is a mixed blessing: A competitor's plant fire created a supply gap that lifted BOPP margins to ~30%, but Uflex's capacity is skewed toward the lower-margin BOPET segment, so the net mix effect is adverse.
• Four new projects are the FY27 story: Aseptic expansion, PET recycling, and two overseas facilities are expected to add ~₹3,000 crores top-line and ~₹500 crores EBITDA once operational, with all four targeted by Q1 FY27.
• Debt peaks then declines: An additional ~₹1,950 crores of debt will fund project completion through FY27, but ~₹1,500 crores of existing debt gets repaid in the same window, yielding a net reduction of ~₹500 crores on the FY27 balance sheet.
• What to watch next quarter: Whether the US oil tariff waiver materialises, the pace of commissioning for the Egypt and Mexico projects, and any sign that BOPET import pressure is easing as management expects.

Import Assault & Pricing Strategy

• BOPET imports doubled: H1 BOPET imports into India rose ~120% YoY and BOPP imports ~100% YoY, forcing domestic producers to cut prices to check the inflow. Margins have since improved as importers absorbed losses.
• Europe under siege: Exports diverted from China and Southeast Asia to Europe due to US tariffs, hurting Uflex's European production and sales in Q2. Management expects no quick resolution on dumping into Europe.
• US tariff burden shared: A 25% additional oil-related tariff on packaging exports from India to the US was partially passed to customers; the full 50% pass-through was not possible, and the company bore the residual cost pending a likely waiver this month.
• No price war: Management refuses to match import prices beyond a point, treating the pressure as temporary and preferring to protect margin structure over volume.

Rajesh Bhatia: "Beyond a point, we know that this is temporary. We don't want to get into a price war matching with import. So, there's no point doing that."

Segment & Regional Performance

• Overall packaging film production declined 6% YoY, with the BOPET import drag outweighing pockets of strength.
• Peer context: Cosmo First benefited disproportionately from the BOPP shortage given its capacity mix; Huhtamaki's better results came from restructuring (closing loss-making units), not volume or price gains.

Project Pipeline & Capacity Build-Out

• Four projects, ~₹3,000 crores top-line target: The new aseptic line in India (already commissioned), PET recycling in Noida (by March), WPP in Mexico, and aseptic packaging in Egypt (both possibly slipping to Q1 FY27) are together expected to add ~₹500 crores in EBITDA at decent utilisation.
• New BOPP line at Dharwad: A 54,000-tonnes-per-annum plant announced at a ₹750 crores investment, coming in FY28, partly to meet tax concession commitments and partly to defend market share in South India while West India capacity is disrupted.
• Recycling demand deferred, not destroyed: The government's EPR exemption lets brands carry forward FY26 recycled-content shortfalls into FY27 and FY28, so near-term orders soften. Management expects demand to be better next year when both the backlog and fresh liability hit simultaneously.
• Project debt trajectory: Additional debt of ~₹950 crores by FY27 and another ~₹1,000 crores in FY27 to complete projects, offset by ~₹1,500 crores of repayments through March 2027, yielding a net ₹500 crores reduction.
• Debt-to-EBITDA target revised: The earlier 2.5x target is not achievable; management now looks at ~2.8x on current metrics, or close to 3x once EBITDA from new investments kicks in.

Rajesh Bhatia: "It will be better next year, because you have to fill for it last year shortfall along with that year's liability."

Overcapacity, Investment Logic & Competitive Dynamics

• BOPET overcapacity has two more years to run, per management's estimate, though the response carried low conviction.
• BOPP capacity is coming: Two new plants, each ~1 lakh ton per annum, are expected in India in FY27; one BOPET plant follows in FY28.
• Investing into a downturn is deliberate: Management frames the Dharwad BOPP plant as a counter-cyclical bet: invest when others are not, protect market share, and capture the upside when the cycle turns. The risk is that overcapacity may follow.
• Importers are burning out in BOPET: Management believes BOPET imports will stop because importers are sitting on losses after domestic producers cut prices; BOPP imports continue due to the domestic shortage.
• QCO/BIS norms withdrawn: The government removed BIS compliance requirements for importing several polymer raw materials, which may increase imports and ease raw-material costs, though management was uncertain about the direct packaging-film impact.

Rajesh Bhatia: "I always feel that you should invest in the market when there is no one else investing in your industry and when the cycle changes, you will have the gains."

Cost Philosophy & Operational Stance

• No one-off cost-cutting programme: Management believes topline growth and margin improvement are far larger needle-movers than trimming travel or similar expenses, and that aggressive cost-cutting risks demotivating the organisation. Manpower is retained even when projects are delayed to avoid rehiring costs later.
• Interest costs to ease organically: Floating-rate debt, both dollar and Indian, will automatically reprice lower as rates fall; management did not address whether loan restructuring could accelerate the benefit.
• Consumption tailwind expected: Direct and indirect tax cuts are expected to boost consumption in coming quarters, with packaging positioned as a major beneficiary.

Rajesh Bhatia: "There is always more focus on how to increase the topline, how to improve the margins, which in any business are the largest needle movers, as compared to cutting some of the costs here and there and demotivating the whole organization."

Guidance & Commitments

Key Metrics